Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based drugs for hematologic and inflammatory diseases. Its pipeline includes rusfertide for polycythemia vera and oral peptide candidates for immune-mediated conditions, some advanced with larger pharma partners. The company focuses on constrained peptides designed for potency, selectivity and convenient dosing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 28.3 | — | -11.7 | — |
| Q2 2025 | 5.5 | — | -34.8 | — |
| Q3 2025 | 4.7 | — | -39.3 | — |
| Q4 2025 | 7.4 | — | -44.4 | — |
| Q1 2026 | 56.4 | 99% | 3.8 | — |
| Q2 2026 | 213.5 | 3,749.2% | 162.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Lineage, Inc. (LINE), TG Therapeutics, Inc. (TGTX), InterDigital, Inc. (IDCC), Axsome Therapeutics, Inc. (AXSM), Viavi Solutions Inc. (VIAV), FormFactor, Inc. (FORM)